深圳马峦山华南紫萁群落及其物种多样性特征研究

对深圳马峦山地区华南紫萁占优势的植物群落进行研究,结果表明：华南紫萁群落中共有维管植物48科69属82种,种类组成具有明显的南亚热带性质;年龄结构显示群落的主要优势种属于稳定型种群,群落总体处于稳定状态;群落的频度指数规律为A＞B＜C＞D＞E,与RaunKiaer频度定律、海南岛山地雨林优势种群的频度规律等不相符合;华南紫萁种群树高和个体数百分比显示,种群高度0.3~0.7 m植株占比例较大,种群处于旺盛发展期;物种多样性指数为SP＝16.42,SW＝4.56,均匀度指数为E＝0.33,E′＝0.83,群落物种多样性指数和均匀度指数均较高,接近典型南亚热带常绿阔叶林顶极群落类型。本研究揭示了华南紫萁野外生存状态,为该种的保护和利用提供了基础资料。     

燕山山脉野生欧李群体叶表皮微形态特征研究

利用扫描电子显微镜对同一生境条件下自然生长的燕山山脉野生欧李实生群体（含嫁接类型）叶片表面微形态特征进行观测。结果表明：欧李叶表皮细胞形态存在两种类型,一类是上下表皮细胞向下凹陷相互连接形成蜂窝状,另一类是上下表皮细胞向上隆起近圆形,且上表皮细胞均具条纹状的角质层;叶片上表皮仅有表皮毛而无气孔分布,叶片下表皮仅有气孔分布;气孔突出于表皮细胞,属无规则型,气孔平均长度8.22±1.30 μm,宽度2.55±0.65 μm,大小21.64±8.60μm²,密度836.23±197.16 个/mm²;欧李群体中不同株系间、叶表皮细胞形态不同类别间气孔特征变异程度较大,可作为欧李优异种质选育和抗干旱胁迫研究的指标之一。     

海洋鱼产品品质的影响因素及其标准化

影响海洋鱼产品品质的因素有很多,如鱼体含水量、肉质及传统加工过程中一些原料的用量(如糟制过程中食盐、酒糟等的加入量)、贮藏过程中贮藏条件的改变等,加工和贮藏过程中水分活度、色泽、pH、酸价、过氧化物值、硫化巴比妥酸值、挥发性盐基氮、蛋白质水解程度及微生物等一些指标可以反映海洋鱼产品的品质。本文对影响海洋鱼产品品质的因素及上述指标一些常用的检测方法进行阐述,并简要论述国内外海洋鱼产品的标准化,以期对控制海洋鱼产品品质提供借鉴。     

骨钙素减轻糖尿病大鼠血- 视网膜屏障的损伤

目的:研究骨钙素(Osteocalcin)对链脲佐菌素诱导的糖尿病大鼠血-视网膜屏障的影响。方法:取健康SD大鼠24只,随机分为正常对照组、糖尿病1月(DM1)组、糖尿病骨钙素干预(DM1+OCGY)组。尾静脉注射STZ建立DM模型,成模后DM1+OCGY组腹腔注射骨钙素(2.57 mg.kg-.1d-1),DM1组腹腔注射等量生理盐水,1个月后处死动物。用伊文思蓝方法检测大鼠血-视网膜屏障的改变。结果:造模1月后大鼠视网膜血管渗透性显著增加,共聚焦显微镜显示红色荧光斑点主要分布在视网膜血管周围,给予骨钙素后,红色荧光斑点明显减少,进一步定量显示1M糖尿病大鼠视网膜伊文思蓝含量为57.4±8.7μg.g-1,骨钙素能够改变这种变化,DM1+OCGY组伊文思蓝含量为26.1±3.8μg.g-1。结论:骨钙素能抑制糖尿病视网膜病的血管渗漏,对糖尿病引起的血-视网膜屏障破坏有保护作用。     

非酒精性脂肪肝病大鼠肝脏SOCS-3 的表达与吡格列酮干预研究

目的:探讨SOCS-3在非酒精性脂肪肝病(NAFLD)发病中的作用以及吡格列酮的干预作用。方法:29只雄性SD大鼠随机分为正常对照组(8只),高脂饮食组(21只)。饲养8周后,从高质饮食组随机抽取5只大鼠证实造模成功后,将该组余下的16只大鼠继续以高脂饲料喂养,并随机分为NAFLD对照组(8只);吡格列酮干预组(8只),予以吡格列酮3mg·kg-·1d-1灌胃。16周末,处死所有大鼠,检测血糖、血胰岛素、血脂、肝脏SOCS-3 mRNA和SREBP-1c mRNA表达及肝脏病理学。结果:与正常对照组相比,NAFLD组血糖、血胰岛素、血脂、肝脏脂肪变水平及肝组织SOCS-3 mRNA、SREBP1c mRNA表达显著上调。吡格列酮干预组SOCS-3 mRNA、SREBP-1c mRNA表达较NAFLD组下调,且血糖、血胰岛素、血脂、肝脏脂肪变水平下降。SOCS-3 mRNA表达水平与胰岛素抵抗指数、SREBP-1c mRNA表达水平、肝脂肪变成显著正相关。结论:SOCS-3可能通过胰岛素抵抗及上调肝组织SREBP-1c mRNA表达参与NAFLD发病,吡格列酮能抑制肝脏SOCS-3的表达,对NAFLD有一定治疗作用。     

Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart

Although pentoxifylline (PTXF), a phosphodiesterase inhibitor, has been reported to exert beneficial effects in cardiac bypass surgery, its effect and mechanisms against ischemia-reperfusion (I/R) injury in heart are poorly understood. Because I/R is known to increase the level of tumor necrosis factor (TNF)-alpha in myocardium and PTXF has been shown to depress the production of TNF-alpha in failing heart, this study examined the hypothesis that PTXF may attenuate cardiac dysfunction and reduce TNF-alpha content in I/R heart. For this purpose, isolated rat hearts were subjected to global ischemia for 30 min followed by reperfusion for 2-30 min. Although cardiac dysfunction due to ischemia was not affected, the recovery of heart function upon reperfusion was markedly improved by PTXF treatment. This cardioprotective effect of PTXF was dose dependent; maximal effect was seen at a concentration of 125 microM. TNF-alpha, nuclear factor-kappaB (NF-kappaB), and phosphorylated NF-kappaB contents were decreased in ischemic heart but were markedly increased within 2 min of starting reperfusion. The ratio of cytosolic-to-homogenate NF-kappaB was decreased, whereas the ratio of particulate-to-homogenate NF-kappaB was increased in I/R hearts. These changes in TNF-alpha and NF-kappaB protein contents as well as in NF-kappaB redistribution due to I/R were significantly attenuated by PTXF treatment. The results of this study indicate that the cardioprotective effects of PTXF against I/R injury may be due to reductions in the activation of NF-kappaB and the production of TNF-alpha content.     

Mechanisms of lysophosphatidic acid-induced increase in intracellular calcium in vascular smooth muscle cells

Although lysophosphatidic acid (LPA) is known to cause an increase in intracellular Ca2+ concentration ([Ca2+]i) in vascular smooth muscle cells (VSMCs), the mechanisms of [Ca2+]i mobilization by LPA are not fully understood. In the present study, the effect of LPA on [Ca2+]i mobilization in cultured A10 VSMCs was examined by Fura-2 fluorescence technique. The expression of LPA receptors was studied by immunostaining. LPA was observed to increase [Ca2+]i in a concentration-dependent manner; this increase was dependent on the concentration of extracellular Ca2+. Both sarcolemmal (SL) Na(+)-Ca2+ exchange inhibitors (amiloride, Ni2+ and KB-R7943) and Na(+)-H+ exchange inhibitor (MIA) as well as SL store-operated Ca2+ channel (SOC) antagonists (SK&F 96365, tyrphostin A9 and gadolinium), unlike SL Ca2+ channel antagonists (verapamil and diltiazem), inhibited the LPA-induced increase in [Ca2+]i. In addition, sarcoplasmic reticulum (SR) Ca2+ channel blocker (ryanodine), SR Ca2+ channel opener (caffeine), SR Ca2+ pump ATPase inhibitor (thapsigargin) and inositol 1,4,5-trisphosphate (InsP3) receptor antagonists (xestospongin and 2-aminoethoxydiphenyl borate) were found to inhibit the LPA-induced Ca2+ mobilization. Furthermore, phospholipase C (PLC) inhibitor (U 73122) and protein kinase C (PKC) activator (phorbol 12-myristate 13-acetate) attenuated the LPA-induced increase in [Ca2+]i. These results indicate that Ca2+ mobilization by LPA involves extracellular Ca2+ entry through SL Na(+)-Ca2+ exchanger, Na(+)-H+ exchanger and SL SOCs. In addition, ryanodine-sensitive and InsP(3)-sensitive intracellular Ca2+ pools may be associated with the LPA-induced increase in [Ca2+]i. Furthermore, the LPA-induced [Ca2+]i mobilization in VSMCs seems to be due to the activation of both PLC and PKC.     

Pharmacological basis of different targets for the treatment of atherosclerosis

The development of atherosclerotic plaque is a highly regulated and complex process which occurs as a result of structural and functional alterations in endothelial cells, smooth muscle cells (SMCs), monocytes/macrophages, T-lymphocytes and platelets. The plaque formation in the coronary arteries or rupture of the plaque in the peripheral vasculature in latter stages of atherosclerosis triggers the onset of acute ischemic events involving myocardium. Although lipid lowering with statins has been established as an important therapy for the treatment of atherosclerosis, partially beneficial effects of statins beyond decreasing lipid levels has shifted the focus to develop newer drugs that can affect directly the process of atherosclerosis. Blockade of renin angiotensin system, augmentation of nitric oxide availability, reduction of Ca(2+) influx, prevention of oxidative stress as well as attenuation of inflammation, platelet activation and SMC proliferation have been recognized as targets for drug treatment to control the development, progression and management of atherosclerosis. A major challenge for future drug development is to formulate a combination therapy affecting different targets to improve the treatment of atherosclerosis.     

大豆β-伴大豆球蛋白基因启动子的克隆及功能分析

通过PCR技术从三个栽培大豆（南农99-10、N2899和南农88－1）和两个野生大豆（江浦野生豆－1和ZYD4174）的基因组中分离到大豆7S蛋白α亚基基因启动子片段(7SαP),序列分析表明：7SαP片段包含多个种子特异性启动子所特有的序列元件,如RY重复序列、ACGT、AGCCCCA等,而这五个大豆材料的7SαP序列的同源性达99%。将从南农99-10中克隆的启动子片段与pBI121-GFP连接构建表达载体,经农杆菌介导转化拟南芥。Southern结果显示, 7SαP 片段和报告基因GFP以单拷贝的形式整合到拟南芥基因组中,且GFP在7SαP驱动下获得了种子特异性表达。     

Ⅰ型单纯疱疹病毒 gD基因片段的高效表达及抗原性分析

目的 获得高表达的Ⅰ型单纯疱疹病毒(HSV)被膜糖蛋白gD（简称gD1）基因的工程菌。方法 通过计算机分析,筛选出疱疹病毒gD1中优势抗原决定簇的基因片段。将克隆的基因片段插入表达载体pTrxA内,转化大肠杆菌Rosetta,以异丙基-β-D-硫代半乳糖苷诱导表达。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析表达产物。　结果　PCR扩增出约930bp的gD1编码基因目的片段,与预期片段大小相符,经测序鉴定无基因突变;所构建pTrxA-gD1重组表达质粒阳性克隆经PCR与双酶切鉴定,与预期结果一致;含有pTrxA-gD1重组质粒的大肠杆菌Rosetta诱导后得到了高效达,SDS-PAGE显示表达产物约Mr48000（Dalton）。免疫印迹结果表明表达产物具有较好的抗原性。结论　成功构建了pTrxA-gD1表达质粒,实现了成熟gD1蛋白在大肠杆菌中的高效表达,表达产物具有好的抗原性。